TML-OTE-MLMs-22

TML-OTE-MLMs-22 is a preclinical-stage topical gel developed by Themis Medicare for the treatment of pain. The formulation utilizes a Novel Drug Delivery System (NDDS) known as Multi-Lamellar Microsystems (MLMs), which are designed to enhance the transdermal delivery and localized efficacy of the active pharmaceutical ingredient. Based on its classification in the Themis pipeline as an NSAID-related candidate (similar to TML-OTE-18-I), it likely functions by inhibiting cyclooxygenase enzymes to reduce inflammation and pain at the application site. The MLM technology aims to provide a sustained release profile and improved skin penetration compared to conventional topical formulations, potentially offering a safer alternative to oral analgesics by minimizing systemic exposure.